CUREVAC ($NASDAQ:CVAC): CureVac N.V., a biopharmaceutical company that specializes in mRNA-based medications, has announced the start of a Phase 2 study of its modified COVID-19 mRNA vaccine candidates, developed in collaboration with GSK. The first participant has been dosed. mRNA, or messenger ribonucleic acid, is an acid that helps direct the creation of proteins in cells. It has been used to develop treatments and vaccines for many diseases, including influenza and cancer, and the COVID-19 mRNA vaccine candidate is the latest development in this field. The vaccine candidates were developed at CureVac’s facilities in Tübingen, Germany, and are being tested in collaboration with GSK’s established adjuvant system. This system is designed to enhance the immune response of the body to the vaccine and is proven to be effective against multiple diseases.
The Phase 2 study is a randomized, observer-blinded trial that will assess the immunogenicity and safety of the vaccine candidates. CureVac N.V. has been a leader in mRNA research for many years and is dedicated to advancing the understanding of mRNA technology and its potential therapeutic benefits. The company’s efforts are backed by strong partnerships with industry partners such as GSK and a robust manufacturing infrastructure. The Phase 2 study marks an important step in their ongoing work to develop safe and effective treatments and vaccines for COVID-19.
The move marks a significant milestone in the development of the vaccine candidates, as it is the first clinical study conducted in Europe for a mRNA-based COVID-19 vaccine. The company’s stock opened at $9.2 and closed at $9.1, down by 2.0% from its last closing price of 9.3. This drop was likely caused by the news that the vaccine has to pass through several more stages of clinical trials before it can be approved. The study is designed to evaluate the safety and immunogenicity of the vaccine candidates and will serve to provide further evidence of their efficacy in combating the coronavirus.
In addition, CUREVAC N.V. has also announced that it will start a Phase 3 clinical trial in the coming weeks, in order to gain additional data on the safety and efficacy of its mRNA-based vaccine candidates. CUREVAC N.V.’s Phase 2 study marks an important step forward in the development of a vaccine against COVID-19, and investors will be keeping a close eye on the progress of the trials and the potential approval of the vaccine in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Curevac N.v. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Curevac N.v. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Curevac N.v. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Curevac N.v are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Curevac N.v Stock Intrinsic Value
At GoodWhale, we have conducted an analysis of CUREVAC N.V.’s financials. Based on our proprietary Valuation Line, the fair value of CUREVAC N.V share is estimated to be around $26.8. However, its current stock price is only $9.1, which is a 66.1% discount from its estimated fair price. This indicates that the stock is currently undervalued, presenting a potential buying opportunity for investors. More…
Risk Rating Analysis
Star Chart Analysis
The race to develop a coronavirus vaccine is heating up, with CureVac NV joining Moderna Inc, BioNTech SE, and Novavax Inc in the race to create a working vaccine. All four companies are racing to create a vaccine that can be used to protect people from the deadly virus. The competition between the companies is fierce, and each is hoping to be the first to develop a working vaccine.
Moderna Inc is a clinical stage biotechnology company that focuses on the discovery, development, and commercialization of therapeutics and vaccines based on messenger RNA (mRNA). As of 2022, Moderna has a market capitalization of $60.86 billion and a return on equity of 55.93%. The company’s mRNA platform has the potential to create medicines for a wide range of diseases and conditions, including cancer, infectious diseases, and rare genetic disorders. Moderna’s most advanced mRNA product candidates are in clinical trials for the treatment of COVID-19, influenza, and RSV.
As of 2022, BioNTech SE has a market cap of 37.45B and a Return on Equity of 63.88%. The company is a biotechnology company that develops and manufactures personalised vaccines against cancer and other infectious diseases.
Novavax Inc is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. The company has a market cap of 1.52B as of 2022 and a ROE of 507.51%. Novavax’s mission is to serve as a global leader in the development, manufacture and commercialization of innovative vaccines to prevent serious and life-threatening infectious diseases.
CureVac N.V. is a promising investment opportunity due to its recent development of modified COVID-19 mRNA vaccine candidates in collaboration with GSK. The company has announced the first dosing of participants in their Phase 2 study and is aiming to advance its vaccine development program rapidly. This has the potential to create significant upside for investors as the vaccine could become a key factor in controlling the current pandemic. CureVac N.V. is also working on other transformative medicines, which could fuel long-term growth if successful.